STOCK TITAN

Immutep - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.

Immutep Limited (IMMP) is a clinical-stage biotechnology leader pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.

Key resources include: Press releases detailing trial results for therapies like IMP321 and IMP701, financial disclosures from global exchanges, partnership announcements with major pharmaceutical collaborators, and scientific presentations demonstrating LAG-3 innovation. All content is sourced directly from company filings and verified channels.

Bookmark this page for streamlined access to Immutep's latest developments in immuno-oncology research, including updates from ongoing clinical programs and analyses of emerging therapeutic strategies. Check regularly for real-time insights into one of biotech's most active immunotherapy pipelines.

Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces constructive feedback from the Paul-Ehrlich-Institut regarding the planned TACTI-004 Phase III trial of eftilagimod alpha for first line treatment of metastatic non-small cell lung cancer. The PEI is supportive of Immutep moving into a registrational trial in first line NSCLC and evaluating efti in combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach that includes chemotherapy. Immutep plans to announce its final trial design for TACTI-004 in Q1 of CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The company also received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program. The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
Immutep Limited (IMM) announces the expansion of the INSIGHT-003 trial to four sites in Germany, supporting faster enrolment in the study evaluating eftilagimod alpha in combination with KEYTRUDA and doublet chemotherapy for NSCLC. The trial is expected to complete recruitment in 1H CY2024, with promising early clinical data showing a 70.6% overall response rate and 10.9-month median progression-free survival in patients with PD-L1 TPS of <50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the completion of patient enrollment in the TACTI-003 Phase IIb trial evaluating efti in combination with pembrolizumab for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The trial enrolled 171 patients in the US, Europe, and Australia, with the primary endpoint being Overall Response Rate. Results are expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
-
Rhea-AI Summary
Immutep Limited announces the completion of the open-label safety lead-in phase of its AIPAC-003 Phase II/III trial. The trial evaluated the combination of 90mg eftilagimod alpha (efti) with paclitaxel in six patients with metastatic breast cancer. There were no safety or tolerability issues, and the independent Data Monitoring Committee recommended proceeding to the randomized Phase II portion of the trial. The Phase II portion will include up to 58 evaluable patients to determine the optimal biological dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial, showing statistically significant increases in Th1 biomarkers and immune activating genes. The data supports the success of eftilagimod alpha (efti) in first-line treatment of non-small cell lung cancer (NSCLC) patients. The increase in absolute lymphocyte count (ALC) is correlated with positive overall survival results. Similar immune response biomarkers were seen in the AIPAC Phase IIb trial in metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
Rhea-AI Summary
Immutep Limited announces its management's participation in upcoming investor events in November. The events include Baird's Biotech Discovery Series and Jefferies London Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
-
Rhea-AI Summary
Immutep Limited provides an update on the development of its product candidates, including positive survival results in the TACTI-002 trial for non-small cell lung cancer (NSCLC). The trial showed a median Overall Survival of 35.5 months, providing an additional 12-18 months compared to historical data. The company is also progressing in other trials for head and neck squamous cell carcinoma (HNSCC) and metastatic breast cancer (MBC). Immutep has a strong cash position of $110.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary
Immutep Limited has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The rebate is for eligible R&D activities conducted in the 2022 fiscal year, specifically related to the TACTI-002 and TACTI-003 clinical studies using its lead compound eftilagimod alpha. Immutep will use the funding to further its current active clinical trial programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
Rhea-AI Summary
Immutep reports promising clinical data from the INSIGHT-003 trial evaluating a triple combination therapy for metastatic non-small cell lung cancer. The therapy showed strong efficacy with a 71.4% Overall Response Rate, 90.5% Disease Control Rate, and a median Progression Free Survival of 10.1 months. The combination also demonstrated positive results in patients with low or negative PD-L1 expression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
Immutep

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

224.16M
146.02M
0.01%
2.06%
3.46%
Biotechnology
Healthcare
Link
Australia
Sydney